Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy

DOI DOI PDF Web Site 参考文献28件

書誌事項

公開日
2024-01-04
資源種別
journal article
権利情報
  • https://www.springernature.com/gp/researchers/text-and-data-mining
  • https://www.springernature.com/gp/researchers/text-and-data-mining
DOI
  • 10.1007/s12282-023-01537-3
  • 10.21203/rs.3.rs-3409142/v1
公開者
Springer Science and Business Media LLC

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p>Background Electronic patient-reported outcomes monitoring (ePROM) is a useful communication tool for patients and healthcare providers in cancer chemotherapy. In this study, we examined the feasibility of our newly developed ePROM system, which we refer to as “Hibilog”. Methods An ePROM app was developed by extracting 18 items from the Patient-Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE). Symptom monitoring was conducted every two weeks for patients with metastatic breast cancer undergoing chemotherapy. The primary outcome was the response rate to the ePROM system. The secondary outcomes were response time, item missing rate, and distribution of responses for each symptom. Results A total of 71 cases (mean age 52.6 years) were analyzed. Performance status was 0 in 76% of the cases and 1 or higher in 24%. First-line treatment was being administered in 30% of cases, second-line treatment in 17%, and third-line or higher treatment in 53%. The response rate to the ePROM system from registration to week 40 remained high at around 80%, indicating good compliance. The average response time was 5.5 min and the missing rate for each item was below 0.3%. Among 1,093 responses, the top 3 symptoms causing interference with daily life were Fatigue (63%), Numbness & tingling (48%), and General pain (46%). Conclusion Our developed ePROM system was able to capture symptoms accurately in patients with metastatic breast cancer undergoing chemotherapy while maintaining a high response compliance.</jats:p>

収録刊行物

  • Breast Cancer

    Breast Cancer 31 (2), 283-294, 2024-01-04

    Springer Science and Business Media LLC

参考文献 (28)*注記

もっと見る

関連プロジェクト

もっと見る

問題の指摘

ページトップへ